Aerie aims multi-kinase inhibitor at retinal disease

The FDA has accepted Aerie Pharmaceuticals’ investigational new drug application for the AR-13503 implant, the company’s treatment candidate for neovascular age-related macular degeneration and diabetic macular edema, the company announced in a press release.
A first-in-human clinical study is planned to begin in the second quarter of this year.
The bio-erodible polyesteramide polymer implant, which delivers a controlled, sustained release of the Rho kinase/protein kinase C inhibitor AR-13503, is designed to be administered by intravitreal injection every 6 months, the release said.

Full Story →